CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: No association in the ARIC study

Cancer Letters

Volumn 207, Issue 2, 2004, Pages 183-189

  Thyagarajan, Bharat ^a   Brott, Marcia ^b   Mink, Pamela ^c   Folsom, Aaron R ^a   Anderson, Kristin E ^a   Oetting, William Starr ^b   Gross, Myron ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c EXPONENT INC   (United States)

Author keywords

Breast cancer; CYP19; CYP1B1; Estrogen metabolism; Prospective study

Indexed keywords

AROMATASE; CYTOCHROME P450; CYTOCHROME P450 1B1; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEIGHT; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; MALE; MENARCHE; MENOPAUSE; NUCLEOTIDE REPEAT; PRIORITY JOURNAL;

AROMATASE; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INCIDENCE; INTRONS; LONGITUDINAL STUDIES; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 1842452781     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.12.009     Document Type: Article

References (30)

1. http://rex.nci.nih.gov/NCI_Pub_Interface/raterisk/rates17.html.
2. Kelsey J.L., Gammon M.D. Epidemiology of breast cancer. Epidemiol. Rev. 12:1990;228-240.
3. Haiman C.A., Hankinson S.E., Spiegelman D., De Vivo I., Colditz G.A., Willett W.C., Speizer F.E., Hunter D.J. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer. 87:2000;204-210.
4. MacLean H.E., Warne G.L., Zajac J.D. Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. J. Neurol. Sci. 135:1996;149-157.
5. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., Sutter T.R. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl Acad. Sci. USA. 93:1996;9776-9781.
6. Savas U., Bhattacharyya K.K., Christou M., Alexander D.L., Jefcoate C.R. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. J. Biol. Chem. 269:1994;14905-14911.
7. Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.Y., Jabs E.W., Li X., Yin H., Cody C.W., Greenlee W.F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269:1994;13092-13099.
8. Spink D.C., Spink B.C., Cao J.Q., DePasquale J.A., Pentecost B.T., Fasco M.J., Li Y., Sutter T.R. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 19:1998;291-298.
9. Li J.J., Li S.A. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc. 46:1987;1858-1863.
10. Newbold R.R., Liehr J.G. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res. 60:2000;235-237.
11. Kim J.H., Stansbury K.H., Walker N.J., Trush M.A., Strickland P.T., Sutter T.R. Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis. 19:1998;1847-1853.
12. Shimada T., Watanabe J., Kawajiri K., Sutter T.R., Guengerich F.P., Gillam E.M., Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 20:1999;1607-1613.
13. Beaumont J.J., Steenland K., Minton A., Meyer S. A computer program for incidence density sampling of controls in case-control studies nested within occupational cohort studies. Am. J. Epidemiol. 129:1989;212-219.
14. Robins J.M., Gail M.H., Lubin J.H. More on Biased selection of controls for case-control analyses of cohort studies. Biometrics. 42:1986;293-299.
15. Prentice R.L. On the design of synthetic case-control studies. Biometrics. 42:1986;301-310.
16. Rothman K.J., Greenland S. Modern, Epidemiology. 1986;Little Brown, Boston.
17. Pearce N., Checkoway H., Dement J. Design and conduct of occupational epidemiology studies: III. Design aspects of case-control studies. Am. J. Ind. Med. 15:1989;395-402.
18. Pearce N. What does the odds ratio estimate in a case-control study? Int. J. Epidemiol. 22:1993;1189-1192.
19. De Vivo I., Hankinson S.E., Li L., Colditz G.A., Hunter D.J. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11:2002;489-492.
20. Bailey L.R., Roodi N., Dupont W.D., Parl F.F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58:1998;5038-5041.
21. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q., Shu X.O., Gao Y.T. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9:2000;147-150.
22. Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K., Higashi Y., Gotoh O., Kawajiri K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 10:2000;25-33.
23. Lee K.M., Abel J., Ko Y., Harth V., Park W.Y., Seo J.S., Yoo K.Y., Choi J.Y., Shin A., Ahn S.H., Noh D.Y., Hirvonen A., Kang D. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br. J. Cancer. 88:2003;675-678.
24. Kocabas N.A., Sardas S., Cholerton S., Daly A.K., Karakaya A.E. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch. Toxicol. 76:2002;643-649.
25. Baxter S.W., Choong D.Y., Eccles D.M., Campbell I.G. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis. 22:2001;347-349.
26. Healey C.S., Dunning A.M., Durocher F., Teare D., Pharoah P.D., Luben R.N., Easton D.F., Ponder B.A. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis. 21:2000;189-193.
27. Suspitsin E.N., Grigoriev M.Y., Togo A.V., Kuligina E.S., Belogubova E.V., Pozharisski K.M., Chagunava O.L., Sokolov E.P., Theillet C., Berstein L.M., Hanson K.P., Imyanitov E.N. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur. J. Cancer. 38:2002;1911-1916.
28. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int. J. Cancer. 89:2000;325-328.
29. Siegelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer. 79:1999;456-463.
30. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics. 8:1998;43-48.